Grant RM, et al. - In the HIV Prevention Trials Network (HPTN) study 067, the Alternative Dosing to Augment preexposure prophylaxis (PrEP) Pill Taking (ADAPT) study, researchers examined if nondaily dosing of oral PrEP may provide equivalent coverage of sex events compared with daily dosing. They randomly assigned at-risk men and transgender women who have sex with men to 1 of 3 dosing regimens: 1 tablet daily, 1 tablet twice weekly with a postsex dose (time-driven), or 1 tablet before and after sex (event-driven), and followed them for coverage of sex events with pre- and postsex dosing measured by weekly self-report, drug concentrations, and electronic drug monitoring. In the Harlem cohort, daily dosing recommendations increased coverage and protective drug concentrations, while in Bangkok, daily and nondaily regimens led to comparably favorable outcomes, where participants had higher levels of education and employment.